Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;4(7):605-618.
doi: 10.4155/cli.14.52.

Outcome measures in amyotrophic lateral sclerosis clinical trials

Sabrina Paganoni  1 , Merit Cudkowicz  2 , James D Berry  2
Affiliations

Outcome measures in amyotrophic lateral sclerosis clinical trials

Sabrina Paganoni et al. Clin Investig (Lond). 2014.

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with an average survival of 3-5 years. While therapies for ALS remain limited, basic and translational ALS research has been host to numerous influential discoveries in recent years. These discoveries have led to a large pipeline of potential therapies that await testing in clinical trials. Until recently, ALS clinical trials have relied on a limited cadre of 'traditional' outcome measures, including survival and measures of function. These measures have proven useful, although imperfect, in Phase III ALS trials. However, their utility in early-phase ALS trials is limited. For these early trials, outcome measures focused on target engagement or biological pathway analysis might improve trial outcomes and better support the drug development process.

Keywords: biomarker; end point; function; surrogate; survival.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1
Figure 1. Framework for biomarker development
Biomarkers are urgently needed in amyotrophic lateral sclerosis for early diagnosis, prognostic determination, monitoring of disease progression and response to treatment.
See this image and copyright information in PMC

References

    1. Brooks BR. Natural history of ALS: symptoms, strength, pulmonary function, and disability. Neurology. 1996;47(4 Suppl. 2):S71–S82. - PubMed
    1. Qureshi M, Schoenfeld DA, Paliwal Y, Shui A, Cudkowicz ME. The natural history of ALS is changing: improved survival. Amyotroph. Lateral Scler. 2009;10(5–6):324–331. - PubMed
    1. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst. Rev. 2012;3:CD001447. - PMC - PubMed
    1. Chio A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118–130. - PMC - PubMed
    1. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000;1(5):293–299. - PubMed

LinkOut - more resources